- New patent paves the way for further market expansion for CAP®Go expression platform
- Patent strengthens CEVEC’s unique position in producing recombinant proteins with tailor-made glycosylation
- Important milestone in establishing CAP®Go as the production standard for difficult-to- express recombinant glycoproteins
Digital lab notebook platform company opens office in Cambridge to support U.S. growth and customer Relations
BERLIN & CAMBRIDGE, Mass. labfolder and the German Accelerator Life Sciences (GALS), an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), today announced the initiation of an extensive collaboration supporting the company’s expansion into the North American markets. With thousands of users and a growing number of customers in the U.S. already, the newly established Cambridge office will accelerate those efforts and support customer relations.
Peppermint VC realizes lucrative exit through the acquisition of next-generation chemotherapy agent CAP7.1 from German biotech CellAct by Mundipharma
CellAct Pharma GmbH together with the Mundipharma global network has announced a new deal for the development and commercialization of smart chemotherapy (CAP7.1) with a total deal value exceeding 250 million €.
What are the latest trends in biotech and digital health funding and why is Germany still using fax machines in healthcare?
a podcast by Tjasa Zajc
with Klaus Stoeckemann, Managing Partner
Emperra GmbH, a start-up company based in Potsdam, Germany, has received the Finance Monthly’s 2017 Game Changers Award. The award is honouring Emperra for its new digital business models, which – based on innovative hardware – enable business revenue to be generated from digital solutions. The 2017 Game Changers Awards honour the innovation and strategic vision of a number of globally recognised specialists across a number of different industrial sectors.
Parties intend to jointly enable AAV production in CEVEC’s CAP(R)GT cells in combination with PlasmidFactory’s broad AAV serotype plasmid portfolio
Collaboration will significantly increase the value of CAP(R)GT for CEVEC customers by broadening the spectrum of available adeno-associated viral (AAV) vectors for gene therapy applications
Reinforcement of senior management team to leverage growth phase of Humedics
Berlin. The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de Buijzer will stay on as managing director (MD) with the title Chief Operations Officer (COO).
Klaus Stoeckemann, PVP Managing Partner, joined Healthtech Invest Europe 2017 in Helsinki/Finland. Watch his opinion on why Finnland is far ahead of Germany when it comes to digitilizing healthcare:
The Berlin-based start-up labfolder has won a second major client: beginning in April 2017, the Berlin Institute of Health (BIH) will be introducing labfolder’s electronic lab notebook as part of its quality initiative. The innovative data management software will be made available to more than 4,000 researchers at the Charité and the Max Delbrück Center for Molecular Medicine.
Project will cover the entire process from R&D up to manufacturing and clinical development of adenoviral vectors for medac’s oncology products using CEVEC’s proprietary CAP(R)GT Technology
Collaboration is next step in setting CAP(R)GT as global standard in adenoviral gene therapy
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications.
Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development
Cologne. CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP(R)GT and CAP(R)Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections.
Determination of liver function is crucial to assess patient’s eligibility for safe liver resection
Berlin. Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that two studies show the potential of the LiMAx test to better assess the eligibility of colorectal cancer patients for liver metastases resection after chemotherapy. The LiMAx test was used to explore the effects of oxaliplatin-based chemotherapy on liver function.
- Submission represents an important step towards establishing CAP(R)GT and CAP(R)Go technologies as the new industrial standards for viral vaccines, commercial-scale gene therapy vectors and recombinant protein production
- CEVEC’s CAP(R) technology licensees can reference BB-MF, simplifying and accelerating their regulatory approval process for a CAP(R)-derived product.
Miracor’s Chairman of the Board: “We are proud to have PVP joining our Investors”
Berlin. Peppermint VenturePartners led the recent Series-C financing of Miracor Medical Systems GmbH with an investment from its Peppermint CBF-1 fund. The total amount raised in the Series-C is currently € 7 Million. Miracor seeks to complete Series-C with another € 8 Million.
- Contract provides up to 11,000 Max Planck scientists access to use labfolder for digital laboratory data Management
- First organization-wide digital laboratory data management deal for a Research institute across all disciplines globally
- Long-term collaboration between labfolder and the Max Planck Society to further develop the platform
- Digitalization of laboratory data management is a key driver in future scientific Innovation
- Agreement establishes Paragon as CEVEC’s preferred partner for contract development and manufacturing (CDMO) services in North America
- Companies will conduct coordinated marketing and business development activities to establish CEVEC’s CAP(R) technologies as a new standard for gene therapy vector production
- Collaboration includes developing a scalable clinical production process for AAV-based gene therapy vectors based on the CAP(R)GT platform
Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that the company has submitted the marketing authorization application for the diagnostic agent necessary for the performance of the LiMAx test. The dossier was submitted in Germany, UK and Austria.
- CAP®GT technology for fully scalable industrial adenoviral vector production with proven absence of replication-competent adenovirus (RCA)
- CAP®GT technology is underway to replace HEK293 as current production host for adenoviral vector
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company’s proprietary cell-expression system, CAP®GT, has delivered the production of safe adenoviral (AV) gene therapy vectors with the proven absence of RCAs.
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will present at the following renowned international scientific cell culture and gene therapy conferences in Europe and the US to promote the unique and superior features of its proprietary platform technologies CAP®Go and CAP®GT to industrial players in biopharmaceutical and gene therapy applications.